Shares of GlaxoSmithKline PLC (NYSE:GSK) have been assigned a consensus rating of “Hold” from the nineteen analysts that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $43.50.
Several brokerages have weighed in on GSK. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. BidaskClub downgraded GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 27th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Wednesday, October 18th. Finally, TheStreet downgraded GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set GlaxoSmithKline PLC (GSK) Target Price at $43.50” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/brokerages-set-glaxosmithkline-plc-gsk-target-price-at-43-50.html.
In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC increased its holdings in shares of GlaxoSmithKline PLC by 16.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after acquiring an additional 457 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in GlaxoSmithKline PLC by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 64 shares during the last quarter. Wealthcare Advisory Partners LLC grew its stake in GlaxoSmithKline PLC by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares during the last quarter. FTB Advisors Inc. grew its stake in GlaxoSmithKline PLC by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after buying an additional 539 shares during the last quarter. Finally, Advisory Services Network LLC grew its stake in GlaxoSmithKline PLC by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after buying an additional 788 shares during the last quarter. Institutional investors and hedge funds own 9.84% of the company’s stock.
Shares of GlaxoSmithKline PLC (NYSE GSK) traded down $0.13 during midday trading on Thursday, reaching $35.06. The company’s stock had a trading volume of 2,585,265 shares, compared to its average volume of 6,662,965. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline PLC has a 12 month low of $34.72 and a 12 month high of $44.53. The stock has a market cap of $86,224.50, a P/E ratio of 12.43, a price-to-earnings-growth ratio of 1.94 and a beta of 1.00.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a $0.5037 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.75%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s dividend payout ratio is presently 163.12%.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.